LV12918B - Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade - Google Patents

Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade Download PDF

Info

Publication number
LV12918B
LV12918B LVP-02-131A LV020131A LV12918B LV 12918 B LV12918 B LV 12918B LV 020131 A LV020131 A LV 020131A LV 12918 B LV12918 B LV 12918B
Authority
LV
Latvia
Prior art keywords
ropivacaine
use according
pharmaceutically acceptable
acceptable salt
concentration
Prior art date
Application number
LVP-02-131A
Other languages
English (en)
Inventor
Arne Torsten Eek
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20390432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LV12918(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of LV12918B publication Critical patent/LV12918B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Claims (10)

  1. LV 12918 IZGUDROJUMA FORMULA 1. Ropivakalna farmaceitiski pieņemama sāls izmantošana medikamenta ražošanā sāpju remdēšanai, kas veic sensoro blokādi un minimālu motorisko blokādi, kas atšķiras ar to, ka ropivakalna koncentrācija ir no 0,01 līdz 0,45 masas %.
  2. 2. Izmantošana saskaņā ar 1. punktu, kas atšķiras ar to, ka ropivakalna koncentrācija preparātā ir 0,1 - 0,3 masas %.
  3. 3. Izmantošana saskaņā ar 2. punktu, kas atšķiras ar to, ka ropivakalna koncentrācija preparātā ir mazāka par 0,2 masas %.
  4. 4. Izmantošana saskaņā ar jebkuru no iepriekšējiem punktiem, kas atšķiras ar to, ka ropivakaīnu ievada ropivakalna hidrohlorīda formā.
  5. 5. Izmantošana saskaņā ar jebkuru no iepriekšējiem punktiem, kas atšķiras ar to, ka ropivakalna farmaceitiski pieņemamu sāli ievada nepārtrauktas infūzijas veidā.
  6. 6. Izmantošana saskaņā ar jebkuru no iepriekšējiem punktiem, kas atšķiras ar to, ka ropivakalna farmaceitiski pieņemamu sāli ievada epidurāli.
  7. 7. Izmantošana saskaņā ar jebkuru no iepriekšējiem punktiem, kas atšķiras ar to, ka ropivakalna farmaceitiski pieņemama sāļa infūziju veic ar padeves ātrumu 10 ml stundā un koncentrāciju šķīdumā ne vairāk par 0,3 masas %. 2
  8. 8. Izmantošana saskaņā ar jebkuru no iepriekšējiem punktiem, kas atšķiras ar to, ka ropivakalna farmaceitiski pieņemamu sāli ievada pēc operācijas sāpju remdēšanai.
  9. 9. Izmantošana saskaņā ar jebkuru no iepriekšējiem punktiem, kas atšķiras ar to, ka ropivakalna farmaceitiski pieņemamu sāli ievada dzemdību sāpju remdēšanai.
  10. 10 15
LVP-02-131A 1993-06-28 2002-07-15 Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade LV12918B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE19939302218A SE9302218D0 (sv) 1993-06-28 1993-06-28 New use

Publications (1)

Publication Number Publication Date
LV12918B true LV12918B (en) 2003-03-20

Family

ID=20390432

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-02-131A LV12918B (en) 1993-06-28 2002-07-15 Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade

Country Status (33)

Country Link
US (2) US5670524A (lv)
EP (1) EP0706395B1 (lv)
JP (1) JP3725541B2 (lv)
CN (1) CN1074918C (lv)
AT (1) ATE216237T1 (lv)
BR (1) BR9406865A (lv)
CA (1) CA2165446C (lv)
CZ (1) CZ283300B6 (lv)
DE (2) DE69430427T2 (lv)
DK (1) DK0706395T3 (lv)
EE (1) EE03205B1 (lv)
ES (1) ES2099048T3 (lv)
FI (1) FI956269A0 (lv)
GR (1) GR970300013T1 (lv)
HK (1) HK1010344A1 (lv)
HU (1) HU218949B (lv)
IL (1) IL110006A (lv)
IS (1) IS4174A (lv)
LT (1) LT3449B (lv)
LV (1) LV12918B (lv)
MY (1) MY119360A (lv)
NO (1) NO955313L (lv)
NZ (1) NZ268110A (lv)
PH (1) PH31258A (lv)
PL (1) PL175518B1 (lv)
PT (1) PT706395E (lv)
RU (1) RU2152215C1 (lv)
SA (1) SA94150010B1 (lv)
SE (1) SE9302218D0 (lv)
SG (1) SG49078A1 (lv)
SK (1) SK280111B6 (lv)
TW (1) TW285640B (lv)
WO (1) WO1995000148A1 (lv)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9302218D0 (sv) * 1993-06-28 1993-06-28 Ab Astra New use
BR9802536A (pt) * 1997-07-21 1999-07-20 Darwin Discovery Ltd Método para anestesiar um paciente humano antes de cirurgias
US20060270708A1 (en) * 2005-05-25 2006-11-30 Navinta Llc Novel process for preparation of isotonic aqueous injection of ropivacaine
US8920843B2 (en) * 2007-11-07 2014-12-30 Svip5 Llc Slow release of organic salts of local anesthetics for pain relief
CA2871821C (en) 2012-05-10 2021-01-12 Painreform Ltd. Depot formulations of a local anesthetic and methods for preparation thereof
JP2016508956A (ja) * 2012-05-10 2016-03-24 セリックスビオ プライヴェート リミテッド 局所疼痛の治療のための組成物と治療法
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
EP2961734B1 (en) 2013-02-28 2018-09-26 Dermira, Inc. Glycopyrrolate salts

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE40994T1 (de) * 1983-08-01 1989-03-15 Astra Laekemedel Ab L-n-n-propylpipekolsaeure-2,6-xylidid und dessen herstellung.
SE9302218D0 (sv) * 1993-06-28 1993-06-28 Ab Astra New use

Also Published As

Publication number Publication date
WO1995000148A1 (en) 1995-01-05
DK0706395T3 (da) 2002-07-22
ES2099048T3 (es) 2002-11-16
PH31258A (en) 1998-06-18
HU218949B (hu) 2001-01-29
FI956269A (fi) 1995-12-27
JP3725541B2 (ja) 2005-12-14
LT3449B (en) 1995-10-25
HUT75115A (en) 1997-04-28
GR970300013T1 (en) 1997-05-31
RU2152215C1 (ru) 2000-07-10
EE03205B1 (et) 1999-08-16
SA94150010B1 (ar) 2006-04-04
CA2165446A1 (en) 1995-01-05
IS4174A (is) 1994-12-29
JPH09500620A (ja) 1997-01-21
TW285640B (lv) 1996-09-11
CZ283300B6 (cs) 1998-02-18
CN1126435A (zh) 1996-07-10
NZ268110A (en) 1999-06-29
SK280111B6 (sk) 1999-08-06
NO955313D0 (no) 1995-12-27
AU7086694A (en) 1995-01-17
DE69430427T2 (de) 2002-11-14
AU692161B2 (en) 1998-06-04
HK1010344A1 (en) 1999-06-17
ATE216237T1 (de) 2002-05-15
FI956269A0 (fi) 1995-12-27
PT706395E (pt) 2002-09-30
HU9503692D0 (en) 1996-02-28
SK164695A3 (en) 1996-07-03
EP0706395B1 (en) 2002-04-17
US5670524A (en) 1997-09-23
LTIP1958A (en) 1995-01-31
SE9302218D0 (sv) 1993-06-28
NO955313L (no) 1995-12-27
BR9406865A (pt) 1996-03-26
CA2165446C (en) 2005-07-05
CZ336495A3 (en) 1996-06-12
IL110006A (en) 1999-01-26
EP0706395A1 (en) 1996-04-17
MY119360A (en) 2005-05-31
SG49078A1 (en) 1998-05-18
PL312198A1 (en) 1996-04-01
IL110006A0 (en) 1994-11-11
DE69430427D1 (de) 2002-05-23
ES2099048T1 (es) 1997-05-16
PL175518B1 (pl) 1999-01-29
CN1074918C (zh) 2001-11-21
US5834489A (en) 1998-11-10
DE706395T1 (de) 1997-09-04

Similar Documents

Publication Publication Date Title
Stanley The history and development of the fentanyl series
Jacobson et al. A dose-response study of intrathecal morphine: efficacy, duration, optimal dose, and side effects
Fischer et al. Comparison of continuous epidural infusion of fentanyl-bupivacaine and morphine-bupivacaine in management of postoperative pain
DE60008374T2 (de) Anästhetische zubereitung enthaltend einen nmda-antagonisten und einen alpha-2 adrenergen agonisten
JP2006213736A (ja) 鎮痛剤およびその使用
US6417201B1 (en) Levobupivacaine as an analgesic agent
JPH09503777A (ja) 慢性痛の処置に有用なレボブピバカイン
JPS61172828A (ja) 外傷後の神経傷害を治療するための薬剤
Wadon et al. Atracurium infusion in the intensive care unit
DE69934305T2 (de) Verwendung von dexmedetomidine zur sedierung auf der intensivstation
JP2001510795A (ja) レボブピバカインとその使用
EP0706395B1 (en) Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade
Freund et al. Caudal anesthesia with lidocaine or bupivacaine: Plasma local anesthetic concentration and extent of sensory spread in old and young patients
JP2620642B2 (ja) 麻薬性鎮痛剤とベンゾジアゼピンとを組み合わせて非経口投与した後に観察される平均血圧の低下を拮抗させるための医薬品
WO2002024181A2 (en) The use of melatonin for induction of general anesthesia
US3959485A (en) Method of reducing intraocular pressure in warm-blooded animals
Reinoso-Barbero et al. Lidocaine with fentanyl, compared to morphine, marginally improves postoperative epidural analgesia in children
US6114370A (en) Amnesic sedation composition and method of administering same
AU692161C (en) Use of ropivacaine in the manufacture of a pharmaceutical with analgetic effect with minimal motor blockade
DE69919191T2 (de) Heilmittel für die stenose des rückenmarkkanals
JPH0213644B2 (lv)
DE69133419T2 (de) Verwendung von Adenosin und Adenosinderivaten für Analgesia
RU2016586C1 (ru) Способ общего обезболивания
Crankshaw Intravenous anaesthetic agents
Corssen Proper Use of Ketamine and Innovar